NEW HUMAN DNA REPAIR ENDONUCLEASE
新人类 DNA 修复核酸内切酶
基本信息
- 批准号:2673245
- 负责人:
- 金额:$ 11.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-07-01 至 2003-06-30
- 项目状态:已结题
- 来源:
- 关键词:DNA repair cell line chemical binding cytosine endonuclease gene expression genetic mapping human tissue immunoprecipitation molecular cloning mutant nucleic acid methylation nucleic acid sequence protein localization protein purification protein structure function site directed mutagenesis southern blotting tissue /cell culture transfection western blottings
项目摘要
DESCRIPTION: (adapted from the investigator's abstract) The maintenance of
genomic integrity relies on the efficacy of DNA repair systems. These
systems counteract the mutational burden imposed on DNA by exogenous
attacks, endogenous reactive species, and errors originating during
replication. Failure of DNA surveillance and repair mechanisms leads to an
increase in the mutation rate, and this, in turn, results in predisposition
to cancer. A prominent role in mutational avoidance and genomic stability
is performed by the DNA mismatch repair system. This system handles base
pair mismatches, short insertions/deletions and recombination-derived
heteroduplexes. Patients with Hereditary Non-Polyposis Colorectal Cancer
(HNPCC) carry a germline mutation in genes involved in DNA mismatch repair
(h MSH2, h MLH1, GTBP /hMSH6, hPMS2 and hPMS1). These genes encode human
homologues of the E. coli mismatch repair proteins MutS and MutL. In the
bacterial system, a third protein, the single-strand endonuclease MutH,
performs the crucial function of strand recognition, incising the newly
synthesized DNA strand carrying the mutation. The new strand is identified
by virtue of the transient lack of adenine methylation at GATC sites. To
date, eukaryotic homologues of MutH, i.e. eukaryotic mismatch repair
endonucleases, have not been identified, and the molecular determinants of
strand discrimination in eukaryotic cells - which lack GATC methylation -
have remained elusive. By employing the yeast interaction trap with hMLH1
as bait , MED1 (mismatch repair endonuclease1), a novel human gene encoding
a protein with homology to bacterial endonucleases, was cloned. Sequence
analysis of MED1 suggests a possible mechanism of strand recognition based
on cytosine methylation at CpG sites. For its interaction with hMLH1 and
homology to bacterial DNA repair proteins, MED1 is a putative mismatch
repair protein and might be a long sought eukaryotic functional homologue of
MutH. Since mismatch repair genes are mutated in HNPCC and sporadic cancers
with microsatellite instability, MED1 is a candidate gene for cancer genetic
testing. Based in these observations, experiments are proposed to address:
1) the biochemical properties of MED1; 2) its functional role in DNA repair.
These studies may provide new insights into the mechanisms of eukaryotic
mismatch repair and further the link between defective DNA repair and
cancer.
描述:(改编自研究者摘要)
基因组完整性依赖于DNA修复系统的功效。 这些
系统抵消了外源基因对DNA造成的突变负担,
攻击,内源性活性物质,以及
复制的 DNA监视和修复机制的失败导致了
突变率的增加,这反过来又会导致易感性
到癌症 在避免突变和基因组稳定性方面的突出作用
是由DNA错配修复系统完成的 该系统处理基础
配对错配、短插入/缺失和重组衍生的
异源双链体。 遗传性非息肉病性结直肠癌患者
(HNPCC)在参与DNA错配修复的基因中携带种系突变
(hMSH 2、hMLH 1、GTBP /hMSH 6、hPMS 2和hPMS 1)。 这些基因编码人类
E.大肠杆菌错配修复蛋白MutS和MutL。 在
细菌系统,第三种蛋白质,单链核酸内切酶MutH,
执行链识别的关键功能,切割新的
携带突变的合成DNA链。 新的链被识别
这是由于GATC位点上腺嘌呤甲基化的短暂缺失。 到
date,MutH的真核同源物,即真核错配修复
核酸内切酶,还没有被确定,和分子决定因素,
在缺乏GATC甲基化的真核细胞中,
仍然难以捉摸。 通过使用酵母相互作用陷阱与hMLH 1
作为诱饵,MED 1(错配修复核酸内切酶1),一种新的人类基因编码
克隆了一种与细菌内切核酸酶具有同源性的蛋白。 序列
MED 1的分析表明,基于链识别的可能机制
在CpG位点的胞嘧啶甲基化。 对于其与hMLH 1的相互作用,
与细菌DNA修复蛋白同源,MED 1是一个假定的错配
修复蛋白,可能是一个长期寻找的真核生物功能同源物,
MutH。 由于错配修复基因在HNPCC和散发性癌症中发生突变,
MED 1是一个具有微卫星不稳定性的肿瘤遗传学候选基因,
试验. 根据这些观察,建议进行实验,以解决:
1)MED 1的生物化学性质; 2)其在DNA修复中的功能作用。
这些研究可能为真核生物的机制提供新的见解。
错配修复和进一步的DNA修复缺陷之间的联系,
癌
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(3)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ALFONSO BELLACOSA其他文献
ALFONSO BELLACOSA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ALFONSO BELLACOSA', 18)}}的其他基金
Identification of first-in-class epigenetic inhibitors that target Thymine DNA Glycosylase (TDG) for future precision therapy of metastatic melanoma
鉴定针对胸腺嘧啶 DNA 糖基化酶 (TDG) 的一流表观遗传抑制剂,用于未来转移性黑色素瘤的精准治疗
- 批准号:
10310527 - 财政年份:2020
- 资助金额:
$ 11.11万 - 项目类别:
TDG as a novel target to enhance gemcitabine killing of pancreatic cancer cells
TDG作为增强吉西他滨杀伤胰腺癌细胞的新靶点
- 批准号:
8959007 - 财政年份:2015
- 资助金额:
$ 11.11万 - 项目类别:
The MED1 Protein in DNA Damage Response and Repair
DNA 损伤反应和修复中的 MED1 蛋白
- 批准号:
7179292 - 财政年份:1998
- 资助金额:
$ 11.11万 - 项目类别:
Regulation of Genomic and Epigenomic Stability at CpG Sites
CpG 位点基因组和表观基因组稳定性的调控
- 批准号:
8449521 - 财政年份:1998
- 资助金额:
$ 11.11万 - 项目类别:
相似海外基金
Establishment of a Mouse NK Cell Line for Analyzing Tumor Infiltration Processes and Developing a Preclinical Model for Cancer Immunotherapy.
建立小鼠 NK 细胞系,用于分析肿瘤浸润过程并开发癌症免疫治疗的临床前模型。
- 批准号:
23K06731 - 财政年份:2023
- 资助金额:
$ 11.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Proof of usefulness of PDX derived cell line
PDX 衍生细胞系的有用性证明
- 批准号:
23K06616 - 财政年份:2023
- 资助金额:
$ 11.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A novel producer cell line for more efficient manufacturing of viral vector systems
用于更有效地制造病毒载体系统的新型生产细胞系
- 批准号:
10597799 - 财政年份:2023
- 资助金额:
$ 11.11万 - 项目类别:
Genestorian: a web application to document and trace genetic modifications in model organism and cell line collections.
Genestorian:一个网络应用程序,用于记录和追踪模型生物和细胞系集合中的遗传修饰。
- 批准号:
EP/Y024591/1 - 财政年份:2023
- 资助金额:
$ 11.11万 - 项目类别:
Fellowship
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
- 批准号:
10672364 - 财政年份:2022
- 资助金额:
$ 11.11万 - 项目类别:
Developing a stable cell line expressing recombinant sclerostin
开发表达重组硬化素的稳定细胞系
- 批准号:
10385037 - 财政年份:2022
- 资助金额:
$ 11.11万 - 项目类别:
Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer
开发自然杀伤 (NK) 细胞系衍生的细胞外囊泡作为癌症的新治疗方法
- 批准号:
10383462 - 财政年份:2022
- 资助金额:
$ 11.11万 - 项目类别:
A cell culture management platform to improve biomedical reproducibility by combining cell line tracking, low-cost genetic analysis, and riskassessment
细胞培养管理平台,通过结合细胞系追踪、低成本遗传分析和风险评估来提高生物医学重现性
- 批准号:
10483063 - 财政年份:2022
- 资助金额:
$ 11.11万 - 项目类别:
AI-Aided Tool for Day Zero Selection of High Performing Cells for Biopharma Cell Line Development
用于生物制药细胞系开发的高性能细胞零日选择的人工智能辅助工具
- 批准号:
10546865 - 财政年份:2022
- 资助金额:
$ 11.11万 - 项目类别:
Modulating expression of candidate genes to improve lentiviral vector production in stable cell line
调节候选基因的表达以提高稳定细胞系中慢病毒载体的产量
- 批准号:
2752732 - 财政年份:2022
- 资助金额:
$ 11.11万 - 项目类别:
Studentship